SpectronRx

At SpectronRx, Thanksgiving is more than just a holiday. It’s a time to pause and reflect on the incredible community we’re privileged to be part of.? We’re deeply grateful for the support of our customers, who drive us to innovate; the dedication of our brilliant colleagues, who work tirelessly to advance our mission; the collaboration of our partners in transforming healthcare; and the encouragement of our peers, who inspire us daily. Each of you plays a crucial role in our success. Together, we’ve made remarkable progress in advancing nuclear medicine and combating life-threatening diseases through radiopharmaceuticals. Our collective effort has led to better patient outcomes, from developing innovative treatments to improving diagnostic capabilities. And this Thanksgiving, we celebrate not just our achievements but the collective effort that makes it all possible. As we look towards the future, we are filled with hope and inspiration, knowing that we have such a strong and supportive community. Wishing you and your loved ones a joyful and meaningful holiday. Thank you for being a part of our incredible journey.? From all of us at SpectronRx—Happy Thanksgiving! ??? #Thanksgiving #NuclearMedicine #Gratitude #Radiopharmaceuticals #TogetherWeAdvance

Congratulations to the team at Pentixapharm Holding AG on their latest milestone! The first patient was treated in their Phase I/II clinical trial, where the safety and efficacy of Lu177-PentixaTher, an innovative radiopharmaceutical therapy, were evaluated. This promising treatment targets relapsed/refractory CXCR4-positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in adults.? This achievement not only represents progress in the field of targeted therapies but also holds the potential to transform the lives of patients facing these challenging hematological conditions. Kudos to everyone involved in driving this important innovation forward. ???Check out the full announcement here: https://lnkd.in/gKK8MXjv #ClinicalTrials #Radiopharmaceuticals #Oncology #NuclearMedicine

Kudos to our friends at?Telix Pharmaceuticals Limited?on expanding their theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix’s development program will initially focus on the treatment of bladder cancer, rounding out its urology franchise, which includes late-stage therapeutic programs for kidney and prostate cancers. ?? This is a significant leap forward for patients and the medical community, offering new hope and possibilities in the fight against cancer! ?? Dive deeper into this exciting development by reading the full announcement here: https://lnkd.in/guxjvQnj #NuclearMedicine?#PrecisionOncology?#CancerResearch?#theranostics?#Radiopharmaceuticals

In the rapidly evolving world of radiopharmaceuticals, choosing the right partner can make all the difference. At SpectronRx, we're not just another player in the field. We stand out with our innovative approach, cutting-edge technology and unwavering commitment to transforming novel diagnostics and therapeutics into commercial successes. Our best-in-class services are here to help ensure your life-saving innovations are brought to market with precision and care. Ready to experience the SpectronRx difference? Contact our team of experts today! https://www.spectronrx.com #Radiopharmaceuticals #Isotopes #NuclearMedicine #RadiopharmaceuticalDevelopment

Congratulations to the team at Curium Pharma on the success of their ECLIPSE trial! The results show that 177Lu-PSMA-I&T significantly improves radiographic progression-free survival in patients with PSMA-positive metastatic castration-resistant prostate cancer compared to hormone therapy. This pivotal Phase 3 trial marks a significant milestone in prostate cancer treatment, offering new hope to patients worldwide. ?? Read the full announcement here:?https://lnkd.in/gHCaijK4 #ProstateCancer #NuclearMedicine #Oncology #Radiopharmaceuticals

Exciting News from SpectronRx!??? We're thrilled to announce our new partnership with Cellectar Biosciences, Inc. Biosciences for the commercial supply of their groundbreaking cancer therapeutic, iopofosine I 131. SpectronRx's cutting-edge facilities in Indiana and Belgium are set to produce this pioneering treatment, which has demonstrated remarkable efficacy in the CLOVER-WaM pivotal study for patients with relapsed or refractory Waldenstrom’s macroglobulinemia (WM). The promising therapy is also being evaluated in Phase 2 studies for multiple myeloma (MM), CNS lymphoma, and pediatric high-grade gliomas. ???Read more about the announcement here: https://lnkd.in/gcCCgjCv #CellectarBiosciences #SpectronRx #CancerTreatment #Radiopharmaceuticals #NuclearMedicine

Today, we honor and celebrate our veterans. Your courage, commitment, and dedication to our country have made an immeasurable impact, and we are forever grateful. Thank you for your extraordinary contributions and for protecting the freedoms we hold dear. ???? Happy Veterans Day! ???? #VeteransDay #ThankYouVeterans #ServiceAndSacrifice

Career Opportunity Alert! ?? Are you passionate about advancing the field of nuclear medicine? Do you want to be part of a team making a real difference in patient care? ?? We're hiring talented professionals to join the dynamic SpectronRx team! Explore rewarding career opportunities in radiopharmaceuticals and contribute to groundbreaking diagnostics and therapies. ?? Ready to take the next step? Visit our Indeed page and apply today! https://lnkd.in/eFxJR_4V #NuclearMedicine?#Careers?#Hiring?#Radiopharmaceuticals

Exciting News! ?? We are thrilled to announce that SpectronRx has entered into a Manufacturing Services Agreement (MSA) with Plus Therapeutics, Inc. for the production of Rhenium (186Re) Obisbemeda, a pioneering radiotherapy for CNS cancers like leptomeningeal metastases and recurrent glioblastoma. This collaboration will enhance supply chain redundancy and ensure that the demands of late-stage clinical trials and future commercial needs are met effectively. ?? This agreement is also great news for patients, as it marks a significant step in expanding the reach and impact of this innovative treatment. Want to know more? Check out the full story in today’s edition of The Pharma Letter ?? https://lnkd.in/gdrVgsNE #SpectronRx #PlusTherapeutics #CNSCancer #Radiotherapy #InnovationInHealthcare

A new week brings exciting developments for patient care!??? SpectronRx is thrilled to welcome the latest changes announced by the Centers for Medicare & Medicaid Services (CMS) regarding the Hospital Outpatient Prospective Payment System (OPPS) Rule. Effective January 1, 2025, this pivotal rule aims to enhance payments for diagnostic radiopharmaceuticals for U.S. Medicare patients. What does this mean for patient care? The potential for increased sustained access to innovative radiopharmaceuticals is a significant step forward in ensuring better outcomes for all Medicare patients. At SpectronRx, we take pride in being at the forefront of radiopharmaceutical development and manufacturing. Discover how we're leading the charge in enhancing patient care through innovation and dedication. ?? https://www.spectronrx.com #PatientCare #NuclearMedicine #CMSUpdate #SpectronRx #Radiopharmaceuticals